Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
L
LDX
vs
S
S&P/ASX 300
Over the past 12 months, LDX has underperformed S&P/ASX 300, delivering a return of -65% compared to S&P/ASX 300's 3% drop.
Stocks Performance
LDX vs S&P/ASX 300
Performance Gap
LDX vs S&P/ASX 300
Performance By Year
LDX vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Lumos Diagnostics Holdings Ltd
Glance View
Lumos Diagnostics makes rapid diagnostic tests and the small reader devices that can help clinics and doctors get results at the point of care instead of sending samples to a central lab. Its products are designed for use in settings such as doctor’s offices, urgent care centers, hospitals, and drug trial sites where fast decisions matter. The company sells test kits, readers, and related consumables to healthcare customers, distributors, and pharmaceutical companies. Its revenue comes from selling those devices and recurring test cartridges or kits that are used each time a test is run. That gives it a mix of one-time hardware sales and repeat purchases of disposable test products. What sets Lumos apart is that it sits between lab testing and quick bedside screening. It is not trying to replace all lab diagnostics; it focuses on tests that are simple to run, easy to interpret, and useful when speed matters more than sending a sample away. That makes its business tied to both clinical care and the wider market for rapid testing tools.